Core Insights - IQVIA Holdings Analytics Inc. reported strong second-quarter 2025 results, with adjusted earnings of $2.81 per share, exceeding estimates by 1.8% and reflecting a 6.4% year-over-year increase. Total revenues reached $4 billion, surpassing consensus estimates by 1.5% and growing 5.3% from the previous year [1][9]. Financial Performance - The Research and Development segment generated revenues of $2.2 billion, a 2.5% increase year-over-year, while the Technology and Analytics segment saw revenues of $1.6 billion, up 8.9% from the prior year [3][9]. - Contract Sales and Medical Solutions revenues rose 9.3% year-over-year to $188 million, exceeding estimates of $181.9 million. Adjusted EBITDA for the quarter was $910 million, a 2.6% increase from the previous year, beating projections of $899.4 million [4][9]. Cash Flow and Debt - The company ended the quarter with cash and cash equivalents of $2 billion, up from $1.7 billion in the previous quarter. Long-term debt increased to $15.5 billion from $13.1 billion [5]. - Net cash generated from operating activities was $443 million, with capital expenditures of $151 million, resulting in a free cash flow of $292 million for the quarter [5]. 2025 Guidance - IQVIA updated its revenue guidance for 2025 to a range of $16.10-$16.30 billion, higher than the previous estimate and above the Zacks Consensus Estimate of $16.06 billion. However, adjusted EBITDA guidance was lowered to $3.75-$3.825 billion from the previous range [6][7]. - The adjusted EPS guidance was also updated to $11.75-$12.05, with the midpoint of $11.90 exceeding the Zacks Consensus Estimate of $11.84 [7].

Core Viewpoint - IQVIA Holdings Analytics Inc. reported strong first-quarter 2025 results, with earnings and revenues exceeding expectations, indicating positive growth trends in its business segments [1][7]. Financial Performance - Adjusted earnings were $2.70 per share, surpassing the Zacks Consensus Estimate by 2.7% and increasing 6.3% year-over-year [1]. - Total revenues reached $3.8 billion, exceeding the consensus estimate by 1.6% and growing 2.5% from the previous year [1]. - Adjusted EBITDA for the quarter was $883 million, a 2.4% increase from the year-ago quarter, but slightly below projections [5]. Segment Performance - The Research and Development segment generated revenues of $2.1 billion, showing a marginal increase year-over-year and meeting estimates [3]. - Revenues from the Technology and Analytics segment were $1.5 billion, growing 6.4% year-over-year and meeting estimates [4]. - Contract Sales and Medical Solutions revenues decreased 4.2% year-over-year to $181 million, missing estimates [4]. Cash Flow and Debt - Net cash generated from operating activities was $586 million, with capital expenditures of $142 million, resulting in a free cash flow of $426 million [6]. - The company ended the quarter with cash and cash equivalents of $1.7 billion, unchanged from the previous quarter, while long-term debt increased to $13.1 billion [5]. 2025 Guidance - For 2025, IQVIA raised its revenue guidance to $16.00-$16.40 billion, higher than the previous estimate and the Zacks Consensus Estimate of $15.86 billion [7]. - The company expects adjusted EPS in the range of $11.70-$12.10, with the midpoint exceeding the Zacks Consensus Estimate of $11.84 [7]. - Adjusted EBITDA guidance for 2025 is set at $3.76-$3.88 billion [7].